Lemonaid Health

Search documents
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation
Globenewswire· 2025-06-30 12:00
Core Viewpoint - 23andMe Holding Co. has received approval from the U.S. Bankruptcy Court for the sale of its assets and ongoing business operations to TTAM Research Institute for $305 million, marking a significant step in the company's transition to a nonprofit model [1][2]. Group 1: Transaction Details - The sale includes substantially all of 23andMe's assets, such as the Personal Genome Service (PGS) and Research Services business lines, as well as the Lemonaid Health business [2]. - The transaction is expected to close in the coming weeks, pending customary closing conditions [1]. Group 2: Company Mission and Future - The acquisition by TTAM is aimed at continuing 23andMe's mission of helping individuals access and understand their genetic information for health benefits [2][3]. - TTAM, as a nonprofit, will focus on improving public knowledge of DNA and enhancing healthcare access globally [3]. Group 3: Customer Data and Privacy - TTAM is committed to providing customers with choice and transparency regarding their genetic data, including options to change their participation in research [3]. - The organization will adhere to 23andMe's existing privacy policies and implement additional consumer protections for customer data [3].
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
Globenewswire· 2025-06-13 20:22
Core Viewpoint - 23andMe has entered into a definitive agreement to sell substantially all of its assets to TTAM Research Institute for $305 million, following a competitive bidding process that included Regeneron Pharmaceuticals as a backup bidder [2][3]. Group 1: Transaction Details - The sale includes the Personal Genome Service (PGS), Research Services business lines, and Lemonaid Health business [2]. - The transaction is subject to approval by the U.S. Bankruptcy Court, with a hearing scheduled for June 17, 2025 [7]. - The agreement with TTAM will replace a previously announced acquisition agreement with Regeneron for $256 million [5]. Group 2: Privacy and Consumer Protections - TTAM has committed to comply with 23andMe's privacy policies and applicable laws, ensuring customer data is processed according to existing consents and privacy statements [4]. - Additional consumer protections include honoring customer rights to delete accounts and genetic data, notifying customers before closing, and establishing a Consumer Privacy Advisory Board within 90 days [6]. - TTAM will offer two years of free identity theft monitoring to customers and will continue to allow de-identified data to be used for research [6].